Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$786.14

3.07 (0.39%)

, GOOGL

Alphabet Class A

$811.77

2.2 (0.27%)

15:51
10/13/16
10/13
15:51
10/13/16
15:51

Google, Salesforce showcase new G Suite offerings

Alphabet's (GOOG; GOOGL) Google and Salesforce (CRM) showcased two integrations that the later built on top of G Suite: Salesforce Lightning for Gmail and Sales Cloud integration with Google Sheets. The new offerings join other existing integrations with Google Calendar, Gmail, Drive and Contacts. With Salesforce Lightning for Gmail, sales reps can now review Salesforce records relevant to their emails, add contacts from their address book into Salesforce, and create new Salesforce records, all from within Gmail. The Sales Cloud integration with Sheets, meanwhile, makes it easy for sales reps to link any Salesforce List View to a Google Sheet. Additionally, users can view, edit and delete records within Sheets and sync those changes back to Salesforce.Reference Link

GOOG

Alphabet

$786.14

3.07 (0.39%)

GOOGL

Alphabet Class A

$811.77

2.2 (0.27%)

CRM

Salesforce

$70.76

-1.47 (-2.04%)

  • 23

    Oct

  • 27

    Oct

  • 10

    Nov

  • 15

    Jan

GOOG Alphabet
$786.14

3.07 (0.39%)

10/12/16
WELS
10/12/16
NO CHANGE
WELS
Market Perform
Wells doesn't see Apple as biggest beneficiary from Samsung issues
Wells Fargo analyst Maynard Um attributes the recent rally in shares of Apple (AAPL), at least in part, to Samsung's (SSNLF) issues with its Note 7 phones. Apple gained an incremental $14B in market capitalization at its intraday peak, which the analyst believes embeds more than 3M of incremental iPhone 7 Plus units. Samsung's production halt will help Apple, but other Android vendors with 5.7 inch phones could see a bigger benefit if Android users prefer to stick with Android, Um tells investors in a research note. He points out that LG, Kyocera, and Microsoft (MFST) have 5.7 inch Android phones at U.S. carriers. Um thinks expectations for Apple into earnings "have risen materially." He keeps a Market Perform rating on the iPhone maker. Apple closed yesterday up 25c to $116.30.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Alphabet, Facebook can meet Street estimates, says Wells Fargo
Wells Fargo says that investors are concerned about the ability of Facebook (FB) and Google (GOOG,GOOGL) to meet Street estimates because forecasts continue to indicate that TV's ad share will be relatively stable over the next two years. But Wells says that Facebook and Google will continue to gain share from "non-TV media" and could see increased revenue from "non-advertising marketing services" such as sponsorships and public relations. Wells keeps Outperform ratings on both stocks.
10/06/16
SBSH
10/06/16
NO CHANGE
Target $89
SBSH
Buy
Citi says Salesforce buying Twitter 'nearly impossible' above $28/share
Citi analyst Walter Pritchard believes a Salesforce (CRM) acquisition of Twitter (TWTR) is possible financially but that such a deal would put "significant constraints" on the company for the next three-plus years. The analyst sees "very little reason" for Salesforce to own Twitter and feels the acquisition "would pose a difficult decision" for CEO Marc Benioff and the board. Salesforce closed yesterday down 6%, or $4.21, to $68.42. Recode reported last night that the company is likely the only bidder left for Twitter after Disney (DIS) and Alphabet (GOOG) opted not to pursue a deal while Apple (AAPL) is unlikely. Twitter in pre-market trading is down 14% to $21.50. In order for Salesforce to avoid a shareholder vote, it would have to borrow $7.5B to fund the transaction if Twitter were valued at $20B, or $27.50-$28 per share, Pritchard tells investors in a research note. This is a level that likely constrains the company with little additional borrowing capacity for other deals, the analyst contends. He thinks the deal is "nearly impossible to do" for Salesforce should the bidding for Twitter go above $20B or $28 per share. Pritchard has a Buy rating on Salesforce with an $89 price target.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GOOGL Alphabet Class A
$811.77

2.2 (0.27%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
CRM Salesforce
$70.76

-1.47 (-2.04%)

10/10/16
JPMS
10/10/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees 'opportune entry point' for Salesforce
JPMorgan analyst Mark Murphy believes shares of Salesforce (CRM) are at an "'opportune entry point" following the recent selloff. The pullback has been driven by a "slightly soft" Q2 and concerns about a potentially expensive acquisition of Twitter (TWTR), Murphy tells investors in a research note. After speaking to industry contacts at Dreamforce, the analyst sees a path for the "overhangs to fade" with a "better pace of business in Q3/Q4" as well as the eventual fading of the Twitter discussion. Murphy reiterates an Overweight rating on Salesforce with a $95 price target in a research note titled "The Most Valuable Cloud Asset Is Undeservedly Undervalued."
10/07/16
ADAM
10/07/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce worthy of investor consideration at current levels, says Canaccord
Canaccord analyst Richard Davis came away from the Salesforce (CRM) Dreamforce week more enthused about the company's outlook. The analyst noted the company is growing its revenues 3.5 times faster than it legacy peers. Davis noted the company's CEO said they are very disciplined on price when it comes to acquisitions and believes that they would not be interested in Twitter (TWTR) at its rumored asking price of $28 per share. Davis reiterated his Buy rating and $95 price target on Salesforce shares.
10/07/16
PIPR
10/07/16
NO CHANGE
Target $100
PIPR
Overweight
Piper sees 'clouds parting' on Salesforce valuation
Salesforce CEO Marc Benioff mostly calmed nerves over a potential Twitter (TWTR) acquisition by saying at the company's analyst day, "While we look at everything, we pass on almost everything," Piper Jaffray analyst Alex Zukin tells investors in a research note. The comment does not completely take a deal for Twitter off the table, but the probability of a transformational acquisition is now "dramatically lower," Zukin contends. As such, the analyst feels the "clouds are parting" on Salesforce's valuation "with sunshine ahead." Zukin believes the company has a "clear line of sight" to $10B in revenue in FY17. He keeps an Overweight rating on the shares with a $100 price target. Salesforce closed yesterday up $2.84, or 4%, to $71.26.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.

TODAY'S FREE FLY STORIES

OMED

OncoMed

$3.77

0.04 (1.07%)

16:48
04/24/17
04/24
16:48
04/24/17
16:48
Hot Stocks
OncoMed announces workforce reduction »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ESRX

Express Scripts

$67.25

0.79 (1.19%)

, ANTM

Anthem

$168.41

0.61 (0.36%)

16:46
04/24/17
04/24
16:46
04/24/17
16:46
Hot Stocks
Express Scripts down 12% after contract with Anthem unlikely to be renewed »

In after hours trading,…

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

OI

Owens-Illinois

$21.34

0.83 (4.05%)

16:46
04/24/17
04/24
16:46
04/24/17
16:46
Earnings
Owens-Illinois sees FY17 EPS $2.40-$2.50, consensus $2.43 »

The Company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ESRX

Express Scripts

$67.25

0.79 (1.19%)

16:45
04/24/17
04/24
16:45
04/24/17
16:45
Hot Stocks
Breaking Hot Stocks news story on Express Scripts »

Express Scripts trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

OI

Owens-Illinois

$21.34

0.83 (4.05%)

16:44
04/24/17
04/24
16:44
04/24/17
16:44
Earnings
Owens-Illinois reports Q1 EPS 58c, consensus 53c »

Reports Q1 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:44
04/24/17
04/24
16:44
04/24/17
16:44
Hot Stocks
Federal Reserve, FDIC approve revised Wells Fargo living will »

The Federal Deposit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

ESRX

Express Scripts

$67.25

0.79 (1.19%)

, ANTM

Anthem

$168.41

0.61 (0.36%)

16:43
04/24/17
04/24
16:43
04/24/17
16:43
Hot Stocks
Express Scripts CEO: 'Perplexed' by potential loss of Anthem contract »

Says Anthem deal is…

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

SMMF

Summit Financial Group

$23.00

0.28 (1.23%)

16:41
04/24/17
04/24
16:41
04/24/17
16:41
Hot Stocks
Summit Financial Group announces resolution of litigation »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$80.05

0.77 (0.97%)

, ESRX

Express Scripts

$67.25

0.79 (1.19%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Hot Stocks
Breaking Hot Stocks news story on CVS Health, Express Scripts, Anthem »

CVS up 2% after Express…

CVS

CVS Health

$80.05

0.77 (0.97%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 02

    May

  • 10

    May

  • 18

    May

  • 06

    Jun

NVS

Novartis

$74.61

1.21 (1.65%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Hot Stocks
Novartis expands pact with Amgen to commercialize AMG 334 for migraine »

Novartis (NVS) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

HMN

Horace Mann

$39.25

0.15 (0.38%)

16:39
04/24/17
04/24
16:39
04/24/17
16:39
Earnings
Horace Mann reports Q1 EPS 37c with items, may not compare to consensus 55c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WNC

Wabash

$20.36

0.64 (3.25%)

16:36
04/24/17
04/24
16:36
04/24/17
16:36
Earnings
Breaking Earnings news story on Wabash »

Wabash sees FY17 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 23

    May

  • 24

    May

WFC

Wells Fargo

$53.65

0.65 (1.23%)

16:36
04/24/17
04/24
16:36
04/24/17
16:36
Periodicals
Breaking Periodicals news story on Wells Fargo »

Fed clears Wells Fargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

WNC

Wabash

$20.36

0.64 (3.25%)

16:35
04/24/17
04/24
16:35
04/24/17
16:35
Earnings
Wabash reports Q1 EPS 32c, consensus 27c »

Reports Q1 revenue $363M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 23

    May

  • 24

    May

BCR

C.R. Bard

$302.41

49.34 (19.50%)

, BDX

Becton Dickinson

$177.07

-8.22 (-4.44%)

16:34
04/24/17
04/24
16:34
04/24/17
16:34
General news
On The Fly: Top stock stories for Monday »

Stocks began the session…

BCR

C.R. Bard

$302.41

49.34 (19.50%)

BDX

Becton Dickinson

$177.07

-8.22 (-4.44%)

PPG

PPG

$108.01

2.07 (1.95%)

AKZOY

AkzoNobel

$29.73

1.77 (6.33%)

ARNC

Arconic

$26.10

0.1 (0.38%)

HAS

Hasbro

$101.70

5.67 (5.90%)

SRPT

Sarepta

$34.02

1.41 (4.32%)

W

Wayfair

$43.48

-2.48 (-5.40%)

AMZN

Amazon.com

$907.41

8.88 (0.99%)

HLX

Helix Energy

$6.06

-1.03 (-14.53%)

HAL

Halliburton

$46.75

-0.31 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 23

    May

  • 31

    May

  • 06

    Jun

PII

Polaris Industries

$83.14

1.28 (1.56%)

16:34
04/24/17
04/24
16:34
04/24/17
16:34
Hot Stocks
Polaris Industries discontinuing manufacturing at its plant in Milford, Iowa »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

UIS

Unisys

$11.15

0.2 (1.83%)

16:33
04/24/17
04/24
16:33
04/24/17
16:33
Earnings
Unisys sees FY17 revenue $2.65B-2.75B, consensus $2.71B »

Sees FY17 non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

CVRS

Corindus

16:33
04/24/17
04/24
16:33
04/24/17
16:33
Hot Stocks
Corindus announces strategic partnership with BLOXR »

Corindus Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

HSTM

HealthStream

$23.62

-0.08 (-0.34%)

16:32
04/24/17
04/24
16:32
04/24/17
16:32
Earnings
HealthStream backs FY17 consolidated revenue growth view of 10%-14% »

Consensus $252.3M. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

UIS

Unisys

$11.15

0.2 (1.83%)

16:32
04/24/17
04/24
16:32
04/24/17
16:32
Earnings
Unisys reports Q1 EPS (65c), consensus (60c) »

Reports Q1 revenue $665M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

AMGN

Amgen

$163.14

2.73 (1.70%)

, NVS

Novartis

$74.61

1.21 (1.65%)

16:32
04/24/17
04/24
16:32
04/24/17
16:32
Hot Stocks
Amgen announces expanded collarboration with Novartis for erenumab »

Amgen (AMGN) announced an…

AMGN

Amgen

$163.14

2.73 (1.70%)

NVS

Novartis

$74.61

1.21 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 06

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

HSTM

HealthStream

$23.62

-0.08 (-0.34%)

16:31
04/24/17
04/24
16:31
04/24/17
16:31
Earnings
HealthStream reports Q1 EPS 4c, consensus 4c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

RE

Everest Re

$239.38

5.65 (2.42%)

16:31
04/24/17
04/24
16:31
04/24/17
16:31
Earnings
Everest Re reports Q1 after-tax operating EPS $6.29, consensus $5.31 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

16:31
04/24/17
04/24
16:31
04/24/17
16:31
Options
Preliminary option volume of 18.1M today »

Preliminary option volume…

CTRV

ContraVir Pharmaceuticals

$1.18

-0.23 (-16.31%)

16:30
04/24/17
04/24
16:30
04/24/17
16:30
Syndicate
ContraVir Pharmaceuticals files to sell common stock and warrants »

ContraVir intends to use…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.